医学部

hirano koji

  (平野 耕治)

Profile Information

Affiliation
School of Medicine Faculty of Medicine, Fujita Health University
Degree
Doctor (Medicine)(Nagoya University)

J-GLOBAL ID
200901090646935676
researchmap Member ID
1000225076

Papers

 10
  • Koji Hirano, Hidenori Tanaka, Kumiko Kato, Kaoru Araki-Sasaki
    Clinical ophthalmology (Auckland, N.Z.), 15 609-616, 2021  
    Purpose: In clinical practice we sometimes encounter patients with severe corneal ulcers who have been treated with topical corticosteroids. This study reviewed the clinical features and visual outcomes of these patients and investigated the background of the prescription of topical corticosteroids. Patients and Methods: The medical records of patients who visited the Cornea Service at Fujita Health University Bantane Hospital and were treated for infectious keratitis from April 2016 to March 2020 were retrospectively reviewed. Patients treated with topical corticosteroids before a culture-proven diagnosis were studied in terms of demographics, best-corrected visual acuity at arrival and at last visit, the clinical course after visit, ocular history, and combination therapy by the previous ophthalmologist. Results: Out of the 200 eyes of 197 patients with infectious keratitis, 14 eyes of 14 patients were treated with topical corticosteroids before a culture-proven diagnosis. All 14 patients were referred, as they had severe keratitis that could not be cured with topical antibiotics and corticosteroids. Based on the culture results, we diagnosed Acanthamoeba keratitis (AK) in six patients, fungal keratitis (FK) in two patients, bacterial keratitis (including a suspected case) in two patients, and unknown cause in four patients. Two patients with AK, FK, and unknown keratitis had unfortunate clinical courses and poor visual outcomes. From the information in the referral letters, at least six of the 14 patients were treated with either acyclovir ocular ointment or valaciclovir tablets, along with topical corticosteroids. Conclusion: Application of topical corticosteroids for keratitis that does not respond to empirical antibiotic therapy is harmful since AK or FK is likely involved in these topical antibiotic-resistant cases. Microbiological evidence, as well as a differential diagnosis of herpetic stromal keratitis, is needed when prescribing topical corticosteroid for the treatment of suspected infectious keratitis.
  • 平野耕治, 田中秀典, 岩味未央.
    眼科, 61(7) 763-769, Jul, 2019  Peer-reviewed
  • 堀口正之, 谷川篤宏, 水口忠, 三宅悠三, 田中秀典, 杉本光生, 佐本大輔, 鈴木啓太, 野村僚子, 森本絵美, 成相由依, 関戸康祐, 高御堂祐基, 小池晃央, 小池絵実果, 加藤大輔, 木全正嗣, 筧清香, 島田佳明, 平野耕治, 宮地栄一, 河合房夫, 山田勝啓, 北島延昭, Geoffrey B Arden, Thor Eysteinsson
    日本眼科学会雑誌, 123(3) 226-259, 2019  Peer-reviewedInvited
  • 野倉 一也, 加子 哲治, 蔵地 万里奈, 小高 泰紘, 島田 佳明, 平野 耕治, 赤木 明生, 吉田 眞理
    神経眼科, 35(増補1) 113-113, Nov, 2018  
  • Tanaka H, Hirano K, Horiguchi M
    Case Rep Ophthalmol, 9(1) 238-242, 2018  Peer-reviewed

Misc.

 14
  • Kaoru Araki-Sasaki, Koji Hirano, Yasuhiro Osakabe, Masahiko Kuroda, Kazuko Kitagawa, Hiroshi Mishima, Hiroto Obata, Masakazu Yamada, Naoyuki Maeda, Kohji Nishida, Shigeru Kinoshita
    OPHTHALMOLOGY, 120(6) 1166-1172, Jun, 2013  
    Purpose: To classify secondary corneal amyloidosis (SCA) by its clinical appearance, to analyze the demographics of the patients, and to determine the involvement of lactoferrin. Design: Retrospective, observational, noncomparative, multicenter study. Participants: Twenty-nine eyes of 29 patients diagnosed with SCA by corneal specialists at 9 ophthalmologic institutions in Japan were studied. Methods: The clinical appearance of SCA was determined by slit-lamp biomicroscopy and was classified into 3 types. The demographics of the patients, for example, age, gender, and the duration of the basic disease (trichiasis, keratoconus, and unknown), were determined for each clinical type. Surgically excised tissues were stained with Congo red and antilactoferrin antibody. The postoperative prognosis also was determined. Main Outcome Measures: Clinical appearance of the 3 types of SCA, along with the gender, age, and duration of the basic diseases were determined. Results: Classification of SCA into 3 types based on clinical appearance found 21 cases with gelatinous drop-like dystrophy (GDLD)-like appearance (GDLD type), 3 cases with lattice corneal dystrophy (LCD)-like appearance (LCD type), and 5 cases with the combined type. Patients with the GDLD type were younger (average age: 40.9 years for the GDLD type, 74.3 years for the LCD type, and 46.8 years for the combined type), predominantly women (85.7% for the GDLD type, 33.3% for the LCD type, and 60% for the combined type), and had the basic disease over a longer time (average duration: 22.1 years for the GDLD type, 14.0 for the LCD type, and 11.4 for the combined type). The distribution of the basic diseases (trichiasis vs. keratoconus vs. unknown) was not significantly different for each type. Surgical treatments, for example, phototherapeutic keratectomy, lamellar keratoplasty, and simple keratectomy, resulted in a good resolution in all surgically treated cases. One subject dropped out of the study. Spontaneous resolution was seen in one subject after epilation of the cilia. Amorphous materials in the excised tissues showed positive staining results by Congo red and by antilactoferrin antibody. Conclusions: Secondary corneal amyloidosis can be classified into 3 clinical types based on its clinical appearance. Larger numbers of females and lactoferrin expression were seen in all 3 types. (C) 2013 by the American Academy of Ophthalmology.
  • 平野 耕治, 馬嶋 紘策, 佐々木 香る
    眼科臨床紀要, 5(11) 1060-1060, Nov, 2012  
  • Yukihiro Matsumoto, Yuichi Ohashi, Hitoshi Watanabe, Kazuo Tsubota
    OPHTHALMOLOGY, 119(10) 1954-1960, Oct, 2012  
    Objective: To investigate the dose-dependent efficacy and safety of diquafosol ophthalmic solution for the treatment of dry eye syndrome. Design: Randomized, double-masked, multicenter, parallel-group, placebo-controlled trial. Participants: A total of 286 Japanese patients with dry eye who were prescribed topical diquafosol (1%, n = 96; 3%, n = 96) or placebo ophthalmic solution (n = 94). Methods: After a washout period of 2 weeks, qualified subjects were randomized to receive a single drop of 1% or 3% diquafosol or placebo ophthalmic solutions 6 times per day for 6 weeks. Main Outcome Measures: The primary outcome measure was fluorescein corneal staining score assessment. The secondary outcome measures were Rose Bengal corneal and conjunctival staining scores, tear break-up time (BUT), and subjective symptom assessment. Safety measures were clinical blood and urine examination and recording of adverse events. Results: Fluorescein corneal staining scores significantly improved with both 1% and 3% topical diquafosol compared with placebo at 4 weeks, respectively (P = 0.037, P = 0.002). There was a dose-dependent effect among the groups. Rose Bengal corneal and conjunctival staining scores also improved significantly with both 1% and 3% diquafosol compared with placebo (P = 0.007 and P = 0.004, respectively). Subjective dry eye symptom scores significantly improved with both diquafosol ophthalmic solutions (P < 0.033), although there were no significant differences in BUT compared with placebo. No significant differences between the treatment groups were observed in relation to the occurrence of adverse events. Conclusions: Both 1% and 3% diquafosol ophthalmic solutions are considered effective and safe for the treatment of dry eye syndrome. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1954-1960 (C) 2012 by the American Academy of Ophthalmology.
  • Yukihiro Matsumoto, Yuichi Ohashi, Hitoshi Watanabe, Kazuo Tsubota
    OPHTHALMOLOGY, 119(10) 1954-1960, Oct, 2012  
    Objective: To investigate the dose-dependent efficacy and safety of diquafosol ophthalmic solution for the treatment of dry eye syndrome. Design: Randomized, double-masked, multicenter, parallel-group, placebo-controlled trial. Participants: A total of 286 Japanese patients with dry eye who were prescribed topical diquafosol (1%, n = 96; 3%, n = 96) or placebo ophthalmic solution (n = 94). Methods: After a washout period of 2 weeks, qualified subjects were randomized to receive a single drop of 1% or 3% diquafosol or placebo ophthalmic solutions 6 times per day for 6 weeks. Main Outcome Measures: The primary outcome measure was fluorescein corneal staining score assessment. The secondary outcome measures were Rose Bengal corneal and conjunctival staining scores, tear break-up time (BUT), and subjective symptom assessment. Safety measures were clinical blood and urine examination and recording of adverse events. Results: Fluorescein corneal staining scores significantly improved with both 1% and 3% topical diquafosol compared with placebo at 4 weeks, respectively (P = 0.037, P = 0.002). There was a dose-dependent effect among the groups. Rose Bengal corneal and conjunctival staining scores also improved significantly with both 1% and 3% diquafosol compared with placebo (P = 0.007 and P = 0.004, respectively). Subjective dry eye symptom scores significantly improved with both diquafosol ophthalmic solutions (P < 0.033), although there were no significant differences in BUT compared with placebo. No significant differences between the treatment groups were observed in relation to the occurrence of adverse events. Conclusions: Both 1% and 3% diquafosol ophthalmic solutions are considered effective and safe for the treatment of dry eye syndrome. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1954-1960 (C) 2012 by the American Academy of Ophthalmology.
  • Yukihiro Matsumoto, Yuichi Ohashi, Hitoshi Watanabe, Kazuo Tsubota
    OPHTHALMOLOGY, 119(10) 1954-1960, Oct, 2012  
    Objective: To investigate the dose-dependent efficacy and safety of diquafosol ophthalmic solution for the treatment of dry eye syndrome. Design: Randomized, double-masked, multicenter, parallel-group, placebo-controlled trial. Participants: A total of 286 Japanese patients with dry eye who were prescribed topical diquafosol (1%, n = 96; 3%, n = 96) or placebo ophthalmic solution (n = 94). Methods: After a washout period of 2 weeks, qualified subjects were randomized to receive a single drop of 1% or 3% diquafosol or placebo ophthalmic solutions 6 times per day for 6 weeks. Main Outcome Measures: The primary outcome measure was fluorescein corneal staining score assessment. The secondary outcome measures were Rose Bengal corneal and conjunctival staining scores, tear break-up time (BUT), and subjective symptom assessment. Safety measures were clinical blood and urine examination and recording of adverse events. Results: Fluorescein corneal staining scores significantly improved with both 1% and 3% topical diquafosol compared with placebo at 4 weeks, respectively (P = 0.037, P = 0.002). There was a dose-dependent effect among the groups. Rose Bengal corneal and conjunctival staining scores also improved significantly with both 1% and 3% diquafosol compared with placebo (P = 0.007 and P = 0.004, respectively). Subjective dry eye symptom scores significantly improved with both diquafosol ophthalmic solutions (P < 0.033), although there were no significant differences in BUT compared with placebo. No significant differences between the treatment groups were observed in relation to the occurrence of adverse events. Conclusions: Both 1% and 3% diquafosol ophthalmic solutions are considered effective and safe for the treatment of dry eye syndrome. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1954-1960 (C) 2012 by the American Academy of Ophthalmology.

Presentations

 4

Research Projects

 3

作成した教科書、教材、参考書

 3
  • 件名(英語)
    根木 昭編「眼のサイエンス」眼疾患の謎、文光堂 2010
    概要(英語)
    角膜神経が障害されるとなぜ潰瘍ができるのか?p64-65を分担執筆
  • 件名(英語)
    福井次矢編「今日の治療指針 私はこう治療している2011」医学書院、2011
    概要(英語)
    「感染性角結膜炎」pp1241-1243の執筆を担当
  • 件名(英語)
    眼科グラフィック vol.2 no.5、2013
    概要(英語)
    「角膜異物除去の注意点」pp510-514の執筆を担当